Since the COVID-19 outbreak, Chinese central SOEs have been making all-out efforts to support the battle against the virus not only in medical material production and development but also by transporting supplies to the front-lines, and in other ways as well.
China National Pharmaceutical Group Co., Ltd. (Sinopharm) has used its technology and capacity advantages to develop and produce nucleic acid diagnostic reagents soon after the outbreak of novel coronavirus.
- Timeline of China Releasing Information on COVID-19 and Advancing International Cooperation
- Temporary Quarantine Center under Construction in Quanzhou, E China
- Bangladesh Signs Pact to Make 5m Sinopharm Vaccine Doses
- East China's Yangzhou Builds Two Advanced Air-Inflated Testing Labs